2016
DOI: 10.3350/cmh.2016.0037
|View full text |Cite
|
Sign up to set email alerts
|

Efficacy of switching from adefovir to tenofovir in chronic hepatitis B patients who exhibit suboptimal responses to adefovir-based combination rescue therapy due to resistance to nucleoside analogues (SATIS study)

Abstract: Background/AimsIt remains to be determined whether switching from adefovir (ADV) to tenofovir (TDF) provides better virological outcomes in patients exhibiting suboptimal responses to ADV plus nucleoside analogue (ADV+NA) therapy for NA-resistant chronic hepatitis B (CHB).MethodsIn this prospective trial, patients who showed partial responses (defined as serum hepatitis B virus [HBV] DNA >60 IU/mL) to ADV+NA therapy for NA resistance were randomly allocated to receive TDF plus NA (TDF+NA group, n=16) or to con… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2

Citation Types

1
12
0

Year Published

2016
2016
2023
2023

Publication Types

Select...
6

Relationship

2
4

Authors

Journals

citations
Cited by 10 publications
(13 citation statements)
references
References 30 publications
1
12
0
Order By: Relevance
“…In conclusion, considering the result from current study [ 30 ] and previous studies [ 23 - 26 , 31 ], TDF with or without NAs might be very effective to treat the patient with suboptimal response to ADV-based therapy.…”
supporting
confidence: 54%
See 1 more Smart Citation
“…In conclusion, considering the result from current study [ 30 ] and previous studies [ 23 - 26 , 31 ], TDF with or without NAs might be very effective to treat the patient with suboptimal response to ADV-based therapy.…”
supporting
confidence: 54%
“…In the current issue, Lee et al [ 30 ] conducted a randomized controlled trial to compare the antiviral efficacy comparing between switching to TDF+NAs therapy and continuing current ADV+NA therapy in patients with suboptimal response to ADV-based therapy. They clearly showed that TDF+NAs therapy provide better VR compared to continue ADV+ NA who showed suboptimal response to ADV-based therapy (87.5% vs. 37.5% at 48 weeks, P =0.002).…”
mentioning
confidence: 99%
“…In fact, a similar finding was also reported in the recent SATIS study from Korea, which showed that switching from ADV to TDF could provide better virological outcomes in patients exhibiting suboptimal responses to ADV + NA therapies for NA-resistant CHB. 22 In the present study, only 12 patients had detected NA-resistant mutations, and 10 of them were associated with ADV-associated resistance. Considering that the exposure time to ADV monotherapy was relatively long for those 10 patients (ranging from 72 to 108 weeks), we speculated that the long-term exposure of prior suboptimal response to ADV was the main reason for the occurrence of ADV-resistant mutations in the current study.…”
Section: Discussionmentioning
confidence: 50%
“…To our satisfaction, all those patients achieved ideal virological responses after switching to other treatment strategies (TDF monotherapy or TDF‐based combination therapy, data not shown). In fact, a similar finding was also reported in the recent SATIS study from Korea, which showed that switching from ADV to TDF could provide better virological outcomes in patients exhibiting suboptimal responses to ADV + NA therapies for NA‐resistant CHB . In the present study, only 12 patients had detected NA‐resistant mutations, and 10 of them were associated with ADV‐associated resistance.…”
Section: Discussionmentioning
confidence: 99%
“…[2][3][4] Thus, the therapeutic goal of antiviral therapy has been to sustain viral suppression in terms of an undetectable HBV DNA level. 5 Long-term use of oral antiviral agents is required to maintain the treatment response. However, the efficacy of antivirals has been reduced by the emergence of drug-resistant HBV mutants.…”
mentioning
confidence: 99%